|
| 37845285 | Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma. | Leukemia | 2024 |
| 36306337 | Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphoma. | Blood Adv | 2023 |
| 37756525 | Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy. | Blood | 2023 |
| 37914482 | 10-day decitabine versus 3â¿¿+â¿¿7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial. | Lancet Haematol | 2023 |
| 37566280 | Outcome prediction by interim positron emission tomography and IgM monoclonal gammopathy in diffuse large B-cell lymphoma. | Ann Hematol | 2023 |
| 37291404 | Patient-reported patterns of follow-up care in the 'Aftercare in Blood Cancer Survivors' (ABC) study. | J Cancer Res Clin Oncol | 2023 |
| 37423893 | Dose-dependent expression of GFI1 alters metabolism in the haematopoietic progenitors and MLL::AF9-induced leukaemic cells. | Br J Haematol | 2023 |
| 37142345 | European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours. | Lancet Haematol | 2023 |
| 37001036 | Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma. | Blood | 2023 |
| 37395845 | Preventive health care in blood cancer survivors: results from the ABC study. | J Cancer Res Clin Oncol | 2023 |
| 37091981 | Dose-dependent effect of GFI1 expression in the reconstitution and the differentiation capacity of HSCs. | Front Cell Dev Biol | 2023 |
| 36786491 | Neutropenia-related aspergillosis in non-transplant haematological patients hospitalised under ambient air versus purified air conditions. | Mycoses | 2023 |
| 36584673 | Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. | Cancer Cell | 2023 |
| 36609404 | Publisher Correction: Epigenome-wide analysis of T-cell large granular lymphocytic leukemia identifies BCL11B as a potential biomarker. | Clin Epigenetics | 2023 |
| 36942797 | Diffuse Large B-Cell Lymphoma and Related Entities. | Dtsch Arztebl Int | 2023 |
| 33025472 | [18]F-flutemetamol positron emission tomography in cardiac amyloidosis. | J Nucl Cardiol | 2022 |
| 35357901 | Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index. | J Clin Oncol | 2022 |
| 36044385 | A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma. | Blood Adv | 2022 |
| 36241697 | Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial. | Leukemia | 2022 |
| 36376973 | Epigenome-wide analysis of T-cell large granular lymphocytic leukemia identifies BCL11B as a potential biomarker. | Clin Epigenetics | 2022 |
| 35974101 | Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial. | Leukemia | 2022 |
| 34953740 | Cost-Effectiveness of Shortening Treatment Duration Based on Interim PET Outcome in Patients With Diffuse Large B-cell Lymphoma. | Clin Lymphoma Myeloma Leuk | 2022 |
| 34855243 | Checkpoint immunotherapy of cutaneous squamous cell carcinoma in patients suffering from chronic lymphocytic leukaemia: divergent outcomes in two men treated with PD-1 inhibitors. | J Eur Acad Dermatol Venereol | 2022 |
| 35021600 | Follicular lymphoma grade 3B and diffuse large B-cell lymphoma present a histopathological and molecular continuum lacking features of progression/ transformation. | Haematologica | 2022 |
| 35292679 | A genetic risk score of alleles related to MGUS interacts with socioeconomic position in a population-based cohort. | Sci Rep | 2022 |
| 34792186 | Dexamethasone-mediated inhibition of Notch signalling blocks the interaction of leukaemia and mesenchymal stromal cells. | Br J Haematol | 2022 |
| 34708297 | Impact of germline polymorphisms in genes regulating glucose uptake on positron emission tomography findings and outcome in diffuse large B-cell lymphoma: results from the PETAL trial. | J Cancer Res Clin Oncol | 2022 |
| 32385164 | Interim PET Evaluation in Diffuse Large B-Cell Lymphoma Using Published Recommendations: Comparison of the Deauville 5-Point Scale and the οSUV<sub>max</sub> Method. | J Nucl Med | 2021 |
| 33909455 | Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma. | J Clin Oncol | 2021 |
| 33596105 | Air Pollution and Polyclonal Elevation of Serum Free Light Chains: An Assessment of Adaptive Immune Responses in the Prospective Heinz Nixdorf Recall Study. | Environ Health Perspect | 2021 |
| 33928400 | FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials. | Eur J Nucl Med Mol Imaging | 2021 |
| 34590303 | Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. | Br J Haematol | 2021 |
| 34764342 | Targeting CD38 in acute myeloid leukemia interferes with leukemia trafficking and induces phagocytosis. | Sci Rep | 2021 |
| 34588555 | Monoclonal gammopathy of undetermined significance is associated with prostate cancer in a population-based cohort study. | Sci Rep | 2021 |
| 34523055 | Quantitative evaluation of interim positron emission tomography in peripheral T-cell lymphoma. | EJNMMI Res | 2021 |
| 34575647 | Pregnancies and Neonatal Outcomes in Patients with Sickle Cell Disease (SCD): Still a (High-)Risk Constellation? | J Pers Med | 2021 |
| 34185342 | Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement. | Eur J Haematol | 2021 |
| 34294911 | Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. | Nat Biotechnol | 2021 |
| 34001867 | Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma. | Blood Cancer J | 2021 |
| 33944897 | Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients. | Blood Adv | 2021 |
| 33414374 | Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma. | Blood Cancer J | 2021 |
| 32316399 | Identifying Genetic Lesions in Ocular Adnexal Extranodal Marginal Zone Lymphomas of the MALT Subtype by Whole Genome, Whole Exome and Targeted Sequencing. | Cancers (Basel) | 2020 |
| 32022621 | Metabolic tumor volume, cancer cell fraction, and prognosis - the case of T-cell/histiocyte-rich large B-cell lymphoma. | Leuk Lymphoma | 2020 |
| 31655809 | Etoposide Combined with FLAG Salvage Therapy Is Effective in Multiple Relapsed/Refractory Acute Myeloid leukemia. | Acta Haematol | 2020 |
| 32067259 | Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial. | Hematol Oncol | 2020 |
| 32040489 | CpG stimulation of chronic lymphocytic leukemia cells induces a polarized cell shape and promotes migration in vitro and in vivo. | PLoS One | 2020 |
| 31710995 | Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial. | Eur J Cancer | 2020 |
| 33117517 | Anti-leukemic effect of CDK9 inhibition in T-cell prolymphocytic leukemia. | Ther Adv Hematol | 2020 |
| 33218185 | Genetic Variants of the NKG2C/HLA-E Receptor-Ligand Axis Are Determinants of Progression-Free Survival and Therapy Outcome in Aggressive B-Cell Lymphoma. | Cancers (Basel) | 2020 |
| 33102497 | Pregnancy in Classical Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia-Paroxysmal Nocturnal Hemoglobinuria: A High-Risk Constellation. | Front Med (Lausanne) | 2020 |